Literature DB >> 3544892

Amodiaquine less effective than chloroquine in the treatment of falciparum malaria in the Philippines.

G Watt, G W Long, L Padre, P Alban, R Sangalang, C P Ranoa, L W Laughlin.   

Abstract

Amodiaquine was compared to chloroquine in two groups of Filipino patients with uncomplicated falciparum malaria. Every patient received 25 mg/kg of base orally given over three days. In a hospital study, all eight patients receiving chloroquine cleared their parasitemia by day 6, but six of eight patients receiving amodiaquine failed to clear parasitemia and in four patients there was no response at all (RIII resistance); this difference was significant (P less than 0.01). In a village based study, there was initial clearing of parasitemia in each patient. However, recrudescent infection occurred in all five patients receiving amodiaquine (RI resistance). Five of six falciparum infections were sensitive to chloroquine, while parasitemia reappeared in one patient. In this village, resistance to amodiaquine was significantly more common than resistance to chloroquine (P less than 0.05). To our knowledge, this is the first report of amodiaquine being substantially worse than chloroquine in the treatment of Plasmodium falciparum infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3544892     DOI: 10.4269/ajtmh.1987.36.3

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro.

Authors:  S T Mariga; J P Gil; C Sisowath; W H Wernsdorfer; A Björkman
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 2.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  The disposition of amodiaquine in Zambians and Nigerians with malaria.

Authors:  P A Winstanley; O Simooya; J M Kofi-Ekue; O Walker; L A Salako; G Edwards; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.